Skip to main content

Table 2 Application of MCC950 for treating different pain conditions

From: The NLRP3 inflammasome: an emerging therapeutic target for chronic pain

Pain condition Species Administration route Administration dosage Dosage regimen References
Oxaliplatin-induced CIPN SD rats i.t. 5 μmol/day Once daily for 25 consecutive days [30]
CPIP SD rats i.t. 30 μg/rat Once daily for 7 consecutive days [31]
RR-EAE C57 mice i.g. 50 mg/kg Once daily for 21 consecutive days [32]
FSL1-induced inflammatory pain C57 mice i.p. 10 mg/kg Single dose [33]
NTG-induced migraine C57 mice i.p. 10 mg/kg Once daily for 11 consecutive days [34]
EAP NOD/LtJ non-obese diabetic (NOD) mice i.p. 10 mg/kg Once a day or every other day for a total of 7 treatments [35]
BCP SD rats i.p. 5 mg/kg; 10 mg/kg For acute treatment: single dose [15]
  5 mg/kg; 10 mg/kg For chronic treatment: once daily for 5 consecutive days
Morphine- or fentanyl-induced hyperalgesia Wistar rats i.p. 5 mg/kg Once daily for 7 consecutive days [24]
\